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ABSTRACT
Activation of the major histocompatibility complex
(MHC) by interferon-gamma (IFNc) is a fundamental
step in the adaptive immune response to pathogens.
Here, we show that reorganization of chromatin loop
domains in the MHC is evident within the first 30min
of IFNc treatment of fibroblasts, and that further
dynamic alterations occur up to 6h. These very
rapid changes occur at genomic sites which are
occupied by CTCF and are close to IFNc-inducible
MHC genes. Early responses to IFNc are thus
initiated independently of CIITA, themaster regulator
of MHC class II genes and prepare the MHC for sub-
sequent induction of transcription.
INTRODUCTION
The major histocompatibility complex (MHC) is con-
sidered the most important genomic region in adaptive
and innate immunity, autoimmunity and disease suscepti-
bility (1,2). The locus is remarkable in that its linear
organization into sub-regions containing gene clusters fa-
cilitates highly efﬁcient and coordinated regulation of gene
expression (3). These sub-regions—class I (telomeric),
class III, class II and extended class II (centromeric)—
contain discrete gene families derived from genomic dupli-
cations during evolution (1). The MHC class I and II
regions contain genes encoding HLA molecules which
present antigens to T-cells, while the class III region
contains complement, inﬂammatory and stress response
genes. Most of the class I HLA genes and the class III
genes are constitutively expressed in all somatic cells,
whereas the class II HLA genes are expressed only in
specialized cells in the thymus and dedicated antigen pre-
senting cells (4). In all other cell types, interferon-gamma
(IFNg) and other cytokines up-regulate MHC class II
genes to ensure that a full T-cell response is generated.
IFNg is synthesized by a variety of immune cells,
including CD4+TH1 cells, CD8+ cytotoxic lymphocytes
and natural killer cells in response to mitogenic and anti-
genic stimuli (5). In non-antigen presenting cells, IFNg
induction of MHC expression is initiated by JAK-STAT
signalling from the IFNg receptor to a cascade that
elicits expression of speciﬁc transcription factors (4,6).
These include CIITA, which is recruited to the constitu-
tively bound enhanceosome at promoters of the class I
and II HLA genes. CIITA, in turn, recruits histone
acetyltransferases and histone deacetylases to the chroma-
tin. The whole process takes several hours, with MHC
class II mRNA only detectable after 6 h of IFNg
exposure (7). However, a massive spatial reconﬁguration
of chromatin is evident within the ﬁrst 10min of IFNg
induction, where the entire MHC emerges from the
chromosome territory in a giant chromatin loop (8,9).
This emphasizes the importance of understanding not
only the signalling cascades, but also the chromatin alter-
ations that are rapidly triggered by IFNg.
Long-range promoter–enhancer interactions that are
required for MHC class II gene expression have been
observed after 12 h treatment with IFNg, by which time
transcriptional induction is well established (10,11). Amore
extensive spatial reconﬁguration has been identiﬁed at 24 h
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of IFNg treatment where a large number of genomic
anchors, also known as matrix attachment regions, form
in the MHC class I and II regions, with signiﬁcant enrich-
ment around inducible genes (12). Genomic anchors tether
chromatin to create folds and loops, and bring distal
genomic regions such as promoters and enhancers
together. They are therefore likely to represent a regulatory
mechanism that is widespread across the MHC (13–15).
There are no studies to date on chromatin changes that
occur at the early stages of IFNg induction.
Here, we studied chromatin organization across
the MHC in MRC5 ﬁbroblasts at 30min and 6 h of
IFNg treatment. Detailed maps of genomic anchors
at these time points were compared to untreated cells. In
addition, we examined the DNA-binding proﬁles of
CTCF since it is required for both enhancer–promoter
interactions and expression of MHC class II genes
(10,11,16). CTCF binding sites were found to partition
the MHC locus into domains that remain largely invariant
over the ﬁrst 6 h of IFNg treatment. However, an imme-
diate change in genomic anchors was seen within 30min of
IFNg treatment, where they are recruited to CTCF
binding sites and increase in number progressively up to
6 h. Collectively, these ﬁndings indicate that IFNg
induces a rapid reconﬁguration of the chromatin in the
MHC at CTCF binding sites to poise the region for sub-
sequent transcriptional activation.
MATERIALS AND METHODS
Cell culture and treatment
MRC5 lung ﬁbroblasts were cultured in RPMI-1640
medium supplemented with 10% foetal calf serum and
L-glutamine at 37C in a 5% CO2 atmosphere, and
grown to 70% conﬂuence. Cells were treated with
200 IU/ml of IFNg (recombinant human IFN-g, R&D
Systems) for 30min or 6 h to induce transcriptional
up-regulation in the MHC.
Isolation of genomic anchors
Genomic anchors were isolated from untreated and IFNg
inducedMRC5 cells using 2MNaCl as described previously
(17), except for the step of chromatin digestion which was
carried out overnight with 600U Eco RI (Sigma), 600U
HindIII (NEB), 200U HaeIII (NEB) and 40U BglII
(NEB). DNA containing isolated genomic anchors was
then puriﬁed and the concentration determined using a
NanoDrop ND-1000. For each time point, three biological
replicates were obtained, of which one was used for micro-
array hybridizations and two for RT-PCR validation.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) experiments were
performedusing untreated and IFNg inducedMRC5 cells
as described elsewhere (18). The experiments were per-
formed using polyclonal antibodies against CTCF
(Millipore 07-729) and BRG1 (Sigma SAB4200195). The
chromatin was puriﬁed using a commercial puriﬁcation
kit (QIAmp DNA blood kit) and the DNA concentration
determined using a NanoDrop ND-1000. Four biological
replicates were obtained for each antibody, of which two
were used for microarray hybridizations and two for the
RT-PCR validation.
Array hybridization and data analysis
PuriﬁedDNA (500 ng) samples were labelled with Cy3- and
Cy5-labelled dCTPs using the Agilent labelling kit and
hybridized on custom made 244K genomic microarrays
(Agilent) according to the manufacturer’s protocol. This
array platform contains 240 000 distinct 60-mer oligo-
nucleotide probes spanning the entire MHC locus. The
positions of the oligonucleotide probes were determined
using the NCBI 36 build assembly of the human genome.
The arrays were scanned on anAgilentMicroarray Scanner
G2565BA at 5 mm resolution. The data from ChIP-chip
experiments were normalized with GeneSpring software.
Brieﬂy, a ratio of Cy5 to Cy3 ﬂuorescent intensity (test
signals/control signals) was calculated. For each channel,
the median signals were subtracted from the median fore-
ground signals. Log2 ratios of test/control signal intensity
were created and subsequently normalized by subtracting
the weighted median for each array.
The NGS analyser (Genomatix) was applied for signiﬁ-
cant peak mining. NGS analyser parameters were set as
following: (i) the size of the sliding window is 100 bp, (ii)
the minimum number of reads per cluster (t) was calculated
from the data set applying a Poisson distribution (19). In
order to reduce the possibility of false-positive peaks, the
top 25% positive peaks were selected. A summary of the
values obtained is shown in Supplementary Table S1. All
the data from this study have been submitted toNCBIGene
Expression Omnibus (http://ncbi.nlm.nih.gov/geo/) under
accession number GSE35845.
The four CTCF motifs were identiﬁed using
MatInspector with a core similarity set to 0.75 and a
matrix similarity set to 0.10 (20).
Validation of ChIP-chip data
PCR primers were designed using Primer 3 software
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.
cgi). Real-time PCR was performed using SYBR Green
Jumpstart Taq ReadyMix kit (Sigma Aldrich), 50 ng DNA
and 2 mM primers using Opticon2 (MJ Research). For
each primer pair, standard curves were constructed from
real-time PCR reactions with known amounts of input
DNA and used for product quantitation. Data analysis
was performed using Opticon ampliﬁcation detection
software (MJ Research). The primer sequences used for
the analysis are listed in Supplementary Table S2. The
array enrichment of the selected sequences is shown in
Supplementary Table S3.
RESULTS
Formation of new genomic anchors at the early stages
of IFN-c induction
Genomic anchors were isolated using 2M NaCl extraction
in MRC5 ﬁbroblasts as previously reported (12,21–25),
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and their positions identiﬁed by hybridization onto a high
resolution 60-mer oligonucleotide tiling path microarray
covering the entire MHC (Figure 1). Twenty-four genomic
anchors were identiﬁed across the MHC in untreated
ﬁbroblasts, giving an average distribution of approxi-
mately one anchor every 160 kb. Nineteen anchors were
present in the class I and classical class II regions, and the
remaining ﬁve were within the class III and extended class
II regions. Overall, 62% of the genomic anchors were
located in intergenic regions, while 16% were in introns
and 4% in exons. By 30-min treatment with IFN-g, the
number of genomic anchors had increased across the
MHC 5-fold to 124, giving an average of approximately
one anchor every 30 kb. The greatest increase was present
within the class II region. Anchors are characterized by
AT tracts, topoisomerase binding sites and repetitive se-
quences (15,26,27). Here, we observed that 73% of
anchors at 30min IFN-g treatment have repetitive se-
quences within 1 kb (data not shown). By 6 h, there was
a substantial increase in genomic anchors to 270, giving an
average of approximately one every 14 kb. Half of these
were within the class II region, which constitutes 23% of
the MHC locus but contains the largest number of IFNg
inducible genes. In order to validate the ﬁndings, the
presence or absence of genomic anchors at eight sites
was conﬁrmed using real-time PCR reactions on MRC5
cells at all three time points (Supplementary Figure S1).
While the inter- and intragenic distribution of genomic
anchors was similar at all three time-points, more anchors
were positioned closer to genes after IFNg treatment.
Furthermore, 72% of the anchors present at 30min
IFN-g treatment are also present at 6 h. For example, at
30min, HLA-DRA in the MHC class II region has
genomic anchors at both its 50 and 30 ends. These remain
at 6 h, but additional anchors are recruited closer to
the gene body, as occurs at other IFNg inducible
genes. The number of genomic anchors present within
2 kb of a transcription start site (TSS) in untreated cells
across the MHC was 13, compared to 47 for 30min and
107 for 6 h IFNg treatment, showing the same trend
as our previous study on anchors in the MHC (12). All
HLA-DP, -DQ and –DR genes have an anchored site
within 2 kb of their TSS at 6 h.
Finally, we compared the genomic anchors identiﬁed
here at 30min and 6 h IFN-g with those previously
identiﬁed at 24 h (12). In the current study, we isolated
genomic anchors using additional restriction enzymes
and determined their distribution with a high resolution
MHC microarray platform. The array contained heavily
overlapping tiles of short oligonucleotides and excluded
repetitive sequences. The arrays that were used in our
previous study consisted of marginally overlapping tiles
of 2 kb BACs, which contained repetitive as well as
non-repetitive sequences. Despite these differences, 27.5
and 35.3% of anchors found in the class II region at
30min and 6 h, respectively, are identical to those
identiﬁed previously at 24 h (12). The distribution of
anchors across the MHC and the trends observed upon
IFNg induction are thus consistent between the different
data sets.
Figure 1. Genomic anchors in the MHC. The anchors were identiﬁed in untreated MRC5 ﬁbroblasts, and ﬁbroblasts induced for 30min and 6 h with
IFNg, using high resolution genomic tiling path arrays for the MHC. The number of genomic anchors in each region of the MHC is shown above
the data plots. Selected RefSeq genes from the UCSC genome database (http://genome.ucsc.edu/) are shown below the array data. The different
regions of the MHC are highlighted in different colours: classical class I, pink; classical class III, blue; classical class II, yellow; and extended class II,
green. This colour scheme is used in subsequent ﬁgures.
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Mapping of CTCF binding sites during IFN-c activation
We then identiﬁed the binding sites of CTCF across
the MHC in untreated MRC5 ﬁbroblasts, and ﬁbro-
blasts treated for 30min and 6 h with IFNg, using
ChIP combined with the high resolution microarrays
described above (ChIP-chip) (Figure 2). Real-time PCR
reactions were then performed to validate the ﬁndings
(Supplementary Figure S1). In ﬁbroblasts without
IFNg, 65% of CTCF binding sites are clustered within
the MHC class II region, 29% within the class I region
and the remaining 6% within the class III and extended
class II regions. Most CTCF sites are positioned within
intergenic regions and are, on an average, 10 kb away
from TSS. Unlike genomic anchors which increased in
number upon IFNg treatment, CTCF binding sites
were found to be generally unaffected at 30min and 6 h
with IFN–g. This is in agreement with our previous study
that showed that IFN–g does not lead to transcriptional
up-regulation of CTCF in ﬁbroblasts (12).
A comparison between the CTCF sites in MRC5
cells and in different cell lines (data from ENCODE)
are shown in Supplementary Table S4. Over 70%
overlap is observed using a window size <5 kb. The
discrepancies could be due to experimental differences as
our MRC5 data are obtained using ChIP-chip while the
ENCODE data are obtained using ChIP-seq. Cell-type
speciﬁc differences could also explain the discrepancies,
as seen for two cell lines in ENCODE, HUVEC and
H1ESC, which show an overlap between their CTCF
sites of 50%.
More than 75% of CTCF binding sites identiﬁed across
the MHC in MRC5 ﬁbroblasts contain four motifs which
we have deﬁned as CTCF-01, CTCF-02, CTCF-03 and
CTCF-04 from the Genomatix transcription factor
binding database, calculated from all known sites of
interaction as a position weight matrix (28) (Figure 3).
Three of the four motifs, CTCF-02, CTCF-03 and
CTCF-04, contain the invariant consensus motif,
CCnnnnGnnGGC, which was identiﬁed by Ohlson
(2010) from computational analysis of CTCF motifs
identiﬁed in several other studies (29). The majority
of CTCF binding sites in MRC5 ﬁbroblasts contain the
CTCF-02 motif followed by CTCF-01, CTCF-03 and
CTCF-04 (Supplementary Table S5). In contrast, 75%
of reported CTCF binding sites in CD4, HeLa and
Jurkat cells contain the CTCF-04 motif indicating
cell-type differences (30).
A comparison with genomic anchors shows that in the
absence of IFNg, there is no overlap between the pos-
itions of genomic anchors and sites bound by CTCF.
However, following IFNg induction, the new genomic
anchors are formed progressively at the genomic sites
bound by CTCF. At 30min IFNg, 45 genomic anchors
have formed at CTCF binding sites and this number in-
creases to 75 at 6 h (Figure 4). Further analysis indicates
that the formation of genomic anchors upon IFNg in-
duction at CTCF sites is statistically signiﬁcant
(Supplementary Table S6). These ﬁndings suggest that
CTCF deﬁnes genomic regions that become reconﬁgured
at the very early stages of MHC transcriptional
up-regulation by IFNg.
XL9, a previously described region between
HLA-DRB1 and HLA-DQA1, is required for mediating
promoter–enhancer loop interactions and expression of
these MHC class II genes in Raji Burkitt’s lymphoma B
cells and in A431 epithelial cells after 12-h exposure to
IFNg (10,31). We ﬁnd that XL9 overlaps with sites
that are stably bound by CTCF, and that the region pro-
gressively recruits genomic anchors at 30min and 6 h
(Figure 5). This critical regulatory region thus appears
Figure 2. Genomic regions occupied by CTCF in the MHC. Sites bound by CTCF were identiﬁed in untreated MRC5 ﬁbroblasts, and ﬁbroblasts
treated for 30min and 6 h with IFNg, using a ChIP-chip-based approach. Colour scheme as in Figure 1.
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to mediate chromatin folding at the very early phases of
IFN-g induction.
Binding of BRG1 within domains deﬁned by CTCF
BRG1, a component of the SWI/SNF ATP-dependent
chromatin remodelling complex, is required for both
IFNg dependent induction of CIITA (32,33) and the
rapid formation of giant chromatin loops in the MHC
(9). In order to determine whether the association of
BRG1 with the MHC changes upon IFNg treatment,
we conducted ChIP-chip experiments in untreated ﬁbro-
blasts and ﬁbroblasts treated with IFNg for 30min. In
untreated ﬁbroblasts, BRG1 is present at high frequency,
with 142, 64, 109 and 30 BRG1 binding sites found in the
MHC class I, III, II and extended class II regions, respect-
ively (Figure 6). Over 60% of these sites are located in
intragenic regions or within 2 kb of a TSS. Ten of the 14
HLA genes in the MHC class II region have intragenic
BRG1 binding sites, despite being transcriptionally silent.
Figure 3. Distribution of four CTCF motifs within MHC regions occupied by CTCF. Bars above 0 represent genomic regions in the positive DNA
strand while bars below 0 represent genomic regions in the negative DNA strand. The MHC is represented on the x-axis. The degree of similarity
between the four CTCF motifs and the identiﬁed CTCF binding sites is represented on the y-axis. The sequence of the four CTCF motifs is also
shown.
Figure 4. Genomic anchors are formed at CTCF sites upon IFN-g induction. The analysis was performed using CTCF binding sites and genomic
anchors in untreated MRC5 ﬁbroblasts, and ﬁbroblasts treated for 30min and 6 h with IFNg. Midpoints of the binding sites were compared
between the factors.
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The average distance of all BRG1 sites to a TSS is 5.6 kb.
Less than 10% of BRG1 sites overlap with genomic
anchors or CTCF sites, and the average distance
between BRG1 and CTCF sites is 11 kb indicating a
markedly different distribution. At 30min of IFNg
treatment, few changes are seen in BRG1 binding.
Furthermore, no genomic anchors overlap with BRG1
binding sites in untreated ﬁbroblasts and only two
anchors overlap with BRG1 sites at 30min of IFNg
treatment (Supplementary Table S7).
DISCUSSION
In order to gain new insights into the molecular events in
the MHC during the early stages of IFNg treatment, we
examined the positions of genomic anchors and CTCF
binding sites at 30min IFNg treatment which coincides
with the recruitment of phosphorylated STAT1 to the
MHC (8,9), and at 6 h since it corresponds to the start
of MHC class II gene expression under the inﬂuence of
the MHC class II transactivator CIITA (7). In this study,
we identiﬁed MHC sites which bind to CTCF and become
rapidly reconﬁgured in ﬁbroblasts at the start of IFNg
induction. This reconﬁguration is initiated independently
of CIITA.
The number of genomic anchors in the MHC increases
signiﬁcantly during the ﬁrst 30min of IFNg treatment,
and there is a further increase from 30min to 6 h
indicating progressive changes in higher order chromatin
folding. In agreement with previous ﬁndings on
IFNg-treated ﬁbroblasts for 24 h (12), most of the new
genomic anchors form at the early time points near
Figure 6. Genomic regions occupied by BRG1 in the MHC. Sites bound by BRG1 were identiﬁed in untreated ﬁbroblasts, and ﬁbroblasts treated for
30min with IFNg. Colour scheme as in Figure 1.
Figure 5. Genomic anchors are formed progressively with IFN-g induction. The different elements are shown in MHC class I and class II genes in
untreated MRC5 ﬁbroblasts, and ﬁbroblasts treated for 30min and 6 h with IFNg. The genomic region XL9 is represented as a grey bar shown
adjacent to the HLA-DQA1 gene. Colour scheme as in Figure 1.
Nucleic Acids Research, 2012, Vol. 40, No. 12 5267
IFNg-inducible genes in the MHC class II region.
This region contains the greatest concentration of
IFNg-regulated genes (1). The kinetics of these
pre-transcriptional events is strikingly similar to that of
giant chromatin loop formation (8) and suggests that the
small and large-scale chromatin changes are linked.
Environmental stimuli can thus lead to changes in chro-
matin architecture in the MHC several hours before
the expression of CIITA and the MHC class II genes.
The driver of these structural changes is likely to be the
transcription factor STAT1, which is phosphorylated
and enters the nucleus within minutes of the start of
IFNg treatment (34). Support for this hypothesis is
that in STAT1 negative cells, IFNg cannot induce
up-regulation of transcription or the rapid formation of
giant chromatin loops (9).
CTCF mediates promoter–enhancer interactions that
are essential for both constitutive and inducible MHC
class II expression (10,11,31). In agreement with the
genome-wide distribution of CTCF (35), we observed
that the MHC is bound extensively by CTCF. The distri-
bution of CTCF binding sites is uneven across the
Figure 7. Model of chromatin organization during IFNg induced MHC class II expression in non-antigen presenting cells. The classical MHC class
II genes, HLA-DP, -DQ and -DR, are not expressed in resting cells and the chromatin exists in a poised conﬁguration. Stable CTCF-binding deﬁnes
domains within the MHC, and BRG1 is constitutively associated with promoters and intergenic sequences. Upon activation of the IFNg receptor,
phospho-STAT1 enters the nucleus and binds to DNA. Within 30min, the chromatin conﬁguration in the MHC is signiﬁcantly altered by the
formation of new genomic anchors at sites bound by CTCF. Chromatin folding is mediated by this process, and occurs in intergenic regions and
proximal to promoter sequences. This is accompanied by the formation of giant chromatin loops and chromatin decondensation. Although BRG1
sites remain invariant, IFNg treatment promotes BRG1-dependent histone acetylation, which enhances sequence accessibility for DNA–protein
interactions and chromatin ﬂexibility for looping. This early step in IFNg primes the locus for transcription and is independent of CIITA, which is
detected at HLA class II genes 4–6 h after the start of IFNg treatment. Further reconﬁguration of genomic anchors occurs up to 6 h of IFNg
exposure, to form an optimal platform for effective transcriptional induction of MHC class II genes.
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different MHC classes, since the majority cluster within
the MHC class II region. Many of these binding sites are
intergenic and, importantly, do not change in number or
position with IFNg treatment indicating that CTCF
deﬁnes distinct chromatin domains independent of
transcription.
To determine whether CTCF binding sites are import-
ant at the very early stages of IFNg induction, we
compared their positions with those of genomic anchors.
In untreated ﬁbroblasts, no anchors overlap with CTCF
sites. At 30min of IFNg treatment, new genomic
anchors are formed at CTCF-binding sites and, by 6 h,
they increase substantially in number. IFNg treatment
thus induces a rapid reconﬁguration of chromatin at
genomic sites occupied by CTCF. Experiments using
CTCF-negative cells could reveal whether the protein is
required for the rapid formation of genomic anchors upon
IFNg induction. Studies at the imprinted locus Igf2/H19
show that CTCF interacts with a genomic anchor to form
a looped chromatin structure (36). Our ﬁndings suggest
that the dynamic interactions between CTCF and
genomic anchors change the topology of the MHC
locus and demarcate new domains required for transcrip-
tion. It has also been shown that CTCF mediates
interchromosomal colocalization of Igf2/H19 and Wsb1/
Nf1 (37). It is thus tempting to speculate that the inter-
action of CTCF with genomic anchors is required for the
relocalization of the MHC in a transcriptionally permis-
sive nuclear microenvironment.
BRG1 binding sites are stable over the ﬁrst 30min
of IFN-g induction and do not overlap with either
genomic anchors or CTCF-binding sites. This is consistent
with its previous description as invariant upon IFNg
induction at the CIITA gene locus, although it is essen-
tial for chromatin loop reorganization and CIITA expres-
sion (9,32,33). In a recent genome-wide study of BRG1
binding sites in stimulated and unstimulated CD4+ T
helper cell subsets (naı¨ve, Th1 and Th2), the majority
of binding sites were conserved across the cell types
and one-quarter were unique to each cell subset (38).
BRG1 binding did not correlate with expression, and at
prototypical T-cell lineage loci there was almost identical
binding of BRG1 in Th1 and Th2 cells (38). Taken
together, these ﬁndings suggest that the stable association
of BRG1 facilitates efﬁcient chromatin remodelling in the
MHC within domains deﬁned by CTCF and genomic
anchors.
We thus propose a model for the early stages of MHC
class II activation by IFNg in non-antigen presenting
cells (Figure 7). Poised for activation, the MHC is
compartmentalized by CTCF and is constitutively bound
by BRG1. Within 30min of IFNg exposure,
phospho-STAT1 enters the nucleus and chromatin starts
to be reconﬁgured at sites occupied by CTCF to form
chromatin hubs. This process occurs independently of
CIITA. Further modiﬁcation of chromatin architecture
occurs up to 6 h of IFNg exposure to form an optimal
platform for effective and coordinate expression of MHC
class II genes.
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